8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer
Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
An open randomized phase III study to compare 8 continuous cycles of chemotherapy with 8
cycles of intermittent (2 times 4 cycles) chemotherapy in first line treatment, in
combination with bevacizumab, and second line treatment of patients with HER2/neu negative,
incurable, metastatic or unresectable locally advanced breast cancer.